<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03484286</url>
  </required_header>
  <id_info>
    <org_study_id>SMART-HF</org_study_id>
    <nct_id>NCT03484286</nct_id>
  </id_info>
  <brief_title>Selfcare Management Intervention in Heart Failure</brief_title>
  <acronym>SMART-HF</acronym>
  <official_title>Selfcare Management Intervention in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CareLigo AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region Sk책ne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CareLigo AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A novel tool for self-care enhancement for heart failure (HF) patients has been developed. In
      this randomized controlled trial, patients will be randomized 1:1 to either receive the
      home-based tool (OPTILOGG) or standard care. The intervention will go on for 8 months, and
      outcomes are self-care, quality of life, cardiovascular events (including emergency visits,
      admissions and number of in-hospital days).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be recruited using continuous sampling, and will be approached either in
      connection with being discharged after a heart failure (HF) related event or upon visiting an
      out-patient HF clinic if the patient has been admitted for HF at least once the last year.

      After written consent has been given, demographical data will be noted, and the patient will
      complete two forms: 1 - the European Heart Failure Self-care Behaviour scale 9-item
      questionnaire (EHFScB-9) and 2 - the quality of life assessment tool &quot;EuroQol five dimension
      scale&quot; (EQ5D). Expected time for this is 20 minutes. The baseline demographical data will
      include age, gender, ejection-fraction, New York Heart Association (NYHA)-class, blood
      pressure, heart rate, HF aetiology, and other routine tests for HF visits as outlined in the
      European guidelines for HF treatment.

      After the patient has filled out the two forms, the patient will be randomized to the control
      group (CG) meaning standard care, or the intervention group (IG). Patients allocated to the
      IG will be equipped with the home based self-care enhancement tool OPTILOGG. OPTILOGG assists
      the patient with symptom monitoring and flexible diuretics regimen, as well as education
      about living with HF. It consists of a specialized tablet computer wirelessly connected to a
      weight scale. OPTILOGG is CE-marked. The intervention will be deployed for eight months.
      After the eight months, the patients will be called to a follow-up visit. During the visit
      all data that was collected at baseline/recruitment will be collected again. All
      cardiovascular events for each patient will be retrieved, for the eight months during which
      the intervention was deployed, but also for the following 12 months. These events include
      hospital admissions, ER-visits and number of in-hospital days.

      Based off of previous findings in the literature, target for enrollment was set at 70 + 70
      patients, to achieve statistical significance with 80% power.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Anticipated">March 3, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 3, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallell randomized clinical trial with continuous sampling and a 1:1 randomization.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Cardiovascular events will be adjudicated as &quot;heart failure related&quot; or &quot;not&quot;, by a blinded expert.
Data analysis will be performed by staff blinded to the patients IDs.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Self-care behaviour</measure>
    <time_frame>Eight months</time_frame>
    <description>Registered using the European Heart Failure Self-care Behaviour Scale (EHFScB), a validated instrument for measuring heart failure (HF) self-care behaviour. The questionnaire is made up of 9 items, where the respondent can choose between 5 different answers to each of the 9 statements. Each item thus generates a score between 1 and 5. The total score for the instrument is between 9 and 45, with 9 constituting the best, or most desireable self-care behaviour and 45 the worst.
Data will be analyzed on a group level using Mann-Whitney-U test for independent samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Eight months</time_frame>
    <description>Using the validated instrument EuroQol 5 dimension scale (EQ5D). The respondent classifies his/her health in 5 dimensions, so in essence five questions pertaining to mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each answer has three levels, &quot;none&quot;, &quot;moderate&quot; and &quot;extreme&quot;. These answers are weighted and then a special look-up tabel is used to get a normalized score between 0 and 1, where 0 is death and 1 is perfect health. A difference in 0.10 is considered relevant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of HF related days min the hospital</measure>
    <time_frame>Eight months + additional 12 months.</time_frame>
    <description>All in-hospital days will be adjudicated as HF-related, or non-HF related. The HF-related in-hospital days will then be analyzed on the group level.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of HF admissions</measure>
    <time_frame>Eight months + additional 12 months.</time_frame>
    <description>All admissions will be adjudicated as HF-related or non-HF related, and the frequency of hospital admissions for HF will be analyzed on the group level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of ER-visits</measure>
    <time_frame>Eight months + additional 12 months.</time_frame>
    <description>It is possible that patients get admitted through other pathways than through the ER. To analyze this we will analyze HF-related ER-visits and contrast with HF-admissions to explore potential differences in care pathways between the two groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adherence to the intervention</measure>
    <time_frame>Eight months.</time_frame>
    <description>Each system will register all patient interactions. The adherence for each patient expressed as a frequency will be analyzed. This only pertains to the IG.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subject to standard care. No interventions above and beyond what is deemed standard care for heart failure patients in the region where the study takes place.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: OPTILOGG</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OPTILOGG</intervention_name>
    <description>OPTILOGG is a CE marked class 1m medical device. It consists of a tablet computer and a wirelessly connected weight scale. The system will have some patient specific information regarding the flexible (loop-) diuretics scheme.
The patient will be asked to step on the weight scale daily, and will be shown to some brief information on how to live better with HF, as well as the recommended dose of diuretics that specific day. Every five days the patient will answer three questions about his/her symptoms, namely shortness of breath, fatigue and peripheral edema. The system also contains information that the patient can study at his/her leisure. If the system detects a deterioration in HF status, the patient is encouraged to contact his/her health care provider via telephone.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Patients in the control group will be subject to standard heart failure care.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed heart failure, International classification of diseases (ICD): I50, existing
             or de-novo, in NYHA-class II-IV

          -  Admission for HF within the last 12 months

          -  Filled out consent form

          -  Expected to be able to use the tool, if allocated to the intervention group

        Exclusion Criteria:

          -  Decline to participate

          -  More than mild cognitive impairment

          -  Expectancy of life &lt; 8 months

          -  For other reasons deemed inappropriate to be enrolled, e.g. participating in another
             study affecting standard care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sofia Gerward, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Sk책ne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Blomqvist, MSc</last_name>
    <phone>+46(0)739617729</phone>
    <email>andreas.blomqvist@careligo.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fredrik Westman, MSc</last_name>
    <phone>+46(0)739737970</phone>
    <email>fredrik.westman@careligo.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Region Sk책ne</name>
      <address>
        <city>Lund</city>
        <state>Sk책ne</state>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Sahlin</last_name>
      <phone>+46(0)46-176703</phone>
      <email>daniel.sahlin@skane.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2018</study_first_submitted>
  <study_first_submitted_qc>March 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

